PHVS Pharvaris
- 19.320
- +0.660+3.54%
- 19.320
- 0.0000.00%
Pharvaris News
Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $34
Morgan Stanley analyst Maxwell Skor maintains $Pharvaris(PHVS.US)$ with a buy rating, and maintains the target price at $34.According to TipRanks data, the analyst has a success rate of 0.0% and a tot
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 208.44K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Pharvaris(PHVS.US)$ Officer JOAN MARIE SCHMIDT intends to sell 12,890 shares of its common stock on Jun 11, with a total market value of approximately $208.44K. JOAN
Press Release: Pharvaris Announces Annual Meeting of Shareholders
Pharvaris Announces Annual Meeting of Shareholders ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykin
JMP Securities Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $50
JMP Securities analyst Jonathan Wolleben maintains $Pharvaris(PHVS.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 41.1% and
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG,
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 503.6K in Common Stocks
SEC FILLINGS DISCLOSED/ May 24, $Pharvaris(PHVS.US)$ Officer MORGAN CONN intends to sell 24,557 shares of its common stock on May 24, with a total market value of approximately $503.6K. MORGAN CONN
Form 144 | Pharvaris(PHVS.US) Insider Proposes to Sell 1.45 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 21, $Pharvaris(PHVS.US)$ Insider Berndt Modig intends to sell 70,000 shares of its common stock on May 21, with a total market value of approximately $1.45 million. Bernd
Vicore Expands and Strengthens Its Board of Directors
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema
Pharvaris's Promising Drug Candidate Deucrictibant Bolsters Buy Rating
Pharvaris Is Maintained at Outperform by Wedbush
Pharvaris Is Maintained at Outperform by Wedbush
Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating
Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating.
Analysts Are Bullish on Top Healthcare Stocks: Steris (STE), Pharvaris (PHVS)
Express News | Pharvaris Q1 2024 Adj EPS €(0.52) Beats €(0.56) Estimate
Pharvaris Advances HAE Treatment in Solid Q1 2024
Pharvaris 1Q EUR Loss/Shr 52c >PHVS
Pharvaris 1Q EUR Loss/Shr 52c >PHVS
Pharvaris | 6-K: Report of foreign private issuer (related to financial reporting)
Press Release: Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update -- RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, c
Express News | Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Pharvaris N.V. Q1 EPS EUR -0.52 Vs. Ibes Estimate EUR -0.56
Analysis
Price Target
No Data
